Skip to content

Study · Animal study (in vivo) · dog · 2004

4 results

Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog.

Jansen M, Darby I, Abribat T, Dubreuil P, Ferdinandi ES, Hardy JG

International journal of pharmaceutics1 May 2004Cited by 8 (Europe PMC)

PMID15113616 (opens in a new tab)DOI10.1016/j.ijpharm.2004.02.012 (opens in a new tab)PepBankPUB-15113616
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In dogs, the bioavailability of TH9507 by intratracheal delivery was 41% relative to subcutaneous dosing.

    In plain wordsIn dogs, inhaled TH9507 reached 41% of the level reached by injection under the skin.

    Peptide
    Tesamorelin
    Outcome
    Not applicableRelative bioavailability by inhaled route
    Study

    dogn: not reported in source

    Comparator
    Subcutaneous dosing
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    approximately 375 microg/kg · intratracheal dry powder insufflationAs given in this study (dog).

    Measurements

    Relative bioavailability
    41%
    intratracheal vs subcutaneous

    Source sentences

    Summary
    The bioavailability by the inhaled route was 41% relative to subcutaneous dosing
    1 context sentence
    Summary · context
    Male beagle dogs were administered TH9507 by intratracheal dry powder insufflation and subcutaneous injection at doses of approximately 375 and 38microg/kg, respectively.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In dogs, the absolute bioavailability of TH9507 by intratracheal delivery was estimated at 13%.

    In plain wordsIn dogs, about 13% of inhaled TH9507 reached the blood.

    Peptide
    Tesamorelin
    Outcome
    Not applicableAbsolute bioavailability by inhaled route
    Study

    dogn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    approximately 375 microg/kg · intratracheal dry powder insufflationAs given in this study (dog).

    Measurements

    Absolute bioavailability
    13%
    intratracheal

    Source sentences

    Summary
    with an absolute bioavailability estimated at 13%.
    1 context sentence
    Summary · context
    Male beagle dogs were administered TH9507 by intratracheal dry powder insufflation and subcutaneous injection at doses of approximately 375 and 38microg/kg, respectively.
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    In dogs, the terminal half-life of TH9507 did not differ significantly between intratracheal and subcutaneous administration.

    In plain wordsIn dogs, TH9507 stayed in the body for a similar time after inhaled and injected doses.

    Peptide
    Tesamorelin
    Outcome
    No significant changeTerminal half-life
    Study

    dogn: not reported in source

    Comparator
    Subcutaneous administration
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intratracheal and subcutaneousAs given in this study (dog).

    Measurements

    Terminal half-life
    39 min
    intratracheal
    Terminal half-life
    26 min
    subcutaneous

    Source sentences

    Summary
    No significant difference was observed for the terminal half-life of TH9507 after intratracheal (39min) and subcutaneous (26min) administrations.
    1 context sentence
    Summary · context
    Male beagle dogs were administered TH9507 by intratracheal dry powder insufflation and subcutaneous injection at doses of approximately 375 and 38microg/kg, respectively.
  4. 04AnimalAnimal study (in vivo)Pharmacokinetics

    In dogs, mean residence time of TH9507 was greater after intratracheal than after subcutaneous administration.

    In plain wordsIn dogs, TH9507 stayed in the body longer after an inhaled dose than after an injected dose.

    Peptide
    Tesamorelin
    Outcome
    IncreaseMean residence time
    Study

    dogn: not reported in source

    Comparator
    Subcutaneous administration
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intratracheal and subcutaneousAs given in this study (dog).

    Measurements

    Mean residence time
    74 min
    intratracheal
    Mean residence time
    52 min
    subcutaneous

    Source sentences

    Summary
    The mean residence time (MRT) was greater following intratracheal administration (74min versus 52min; P<0.01).
    1 context sentence
    Summary · context
    Male beagle dogs were administered TH9507 by intratracheal dry powder insufflation and subcutaneous injection at doses of approximately 375 and 38microg/kg, respectively.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.